Idelalisib for relapsed/refractory indolent B-cell non-Hodgkin’s lymphoma: an overview of pharmacokinetics and clinical trial outcomes

References

• Leukemia & Lymphoma Society. Non-Hodgkin Lymphoma. 2013. Available from: https://www.lls.org/content/nationalcontent/resourcecenter/freeeducationmaterials/lymphoma/pdf/nhl.pdf [Last accessed 19 March 2015]
   Google Scholar
• Lunning MA, Vose JM. Management of indolent lymphoma: where are we now and where are we going. Blood Rev 2012;26:279-88
   PubMed Web of Science ®Google Scholar
• Freedman A. Follicular lymphoma: 2014 update on diagnosis and management. Am J Hematol 2014;89:429-36
   PubMed Web of Science ®Google Scholar
• A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin’s lymphoma. The Non-Hodgkin’s Lymphoma Classification Project. Blood 1997;89:3909-18
   PubMed Web of Science ®Google Scholar
• Zelenetz AD, Gordon LI, Wierda WG, et al. Non-Hodgkin's lymphomas, version 2.2014. J Natl Compr Canc Netw 2014;12(6):916-46
   PubMed Web of Science ®Google Scholar
• Colombat P, Salles G, Brousse N, et al. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood 2001;97:101-6
   PubMed Web of Science ®Google Scholar
• Hainsworth JD, Litchy S, Burris HAIII, et al. Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin’s lymphoma. J Clin Oncol 2002;20:4261-7
   PubMed Web of Science ®Google Scholar
• Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005;106:3725-32
   PubMed Web of Science ®Google Scholar
• Marcus R, Imrie K, Solal-Celigny P, et al. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol 2008;26:4579-86
   PubMed Web of Science ®Google Scholar
• Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 2013;381:1203-10
   PubMed Web of Science ®Google Scholar
• Chao MP. Treatment challenges in the management of relapsed or refractory non-Hodgkin’s lymphoma - novel and emerging therapies. Cancer Manag Res 2013;5:251-69
   PubMedGoogle Scholar
• Fowler N, Davis E. Targeting B-cell receptor signaling: changing the paradigm. Hematology Am Soc Hematol Educ Program 2013;2013:553-60
   PubMedGoogle Scholar
• Burger JA, Gribben JG. The microenvironment in chronic lymphocytic leukemia (CLL) and other B cell malignancies: insight into disease biology and new targeted therapies. Semin Cancer Biol 2014;24:71-81
   PubMed Web of Science ®Google Scholar
• Ortiz-Maldonado V, García-Morillo M, Delgado J. The biology behind PI3K inhibition in chronic lymphocytic leukaemia. Ther Adv Hematol 2015;6:25-36
   PubMed Web of Science ®Google Scholar
• Limon JJ, Fruman DA. Akt and mTOR in B cell activation and differentiation. Front Immunol 2012;3:228
   PubMed Web of Science ®Google Scholar
• Vanhaesebroeck B, Guillermet-Guibert J, Graupera M, Bilanges B. The emerging mechanisms of isoform-specific PI3K signalling. Nat Rev Mol Cell Biol 2010;11:329-41
   PubMed Web of Science ®Google Scholar
• Fruman DA, Rommel C. PI3K and cancer: lessons, challenges and opportunities. Nat Rev Drug Discov 2014;13:140-56
   PubMed Web of Science ®Google Scholar
• Westin JR. Status of PI3K/Akt/mTOR pathway inhibitors in lymphoma. Clin Lymphoma Myeloma Leuk 2014;14:335-42
   PubMed Web of Science ®Google Scholar
• Durand CA, Hartvigsen K, Fogelstrand L, et al. Phosphoinositide 3-kinase p110 delta regulates natural antibody production, marginal zone and B-1 B cell function, and autoantibody responses. J Immunol 2009;183:5673-84
   PubMed Web of Science ®Google Scholar
• Bilancio A, Okkenhaug K, Camps M, et al. Key role of the p110delta isoform of PI3K in B-cell antigen and IL-4 receptor signaling: comparative analysis of genetic and pharmacologic interference with p110delta function in B cells. Blood 2006;107:642-50
   PubMed Web of Science ®Google Scholar
• Srinivasan L, Sasaki Y, Calado DP, et al. PI3 kinase signals BCR-dependent mature B cell survival. Cell 2009;139:573-86
   PubMed Web of Science ®Google Scholar
• Okkenhaug K, Bilancio A, Farjot G, et al. Impaired B and T cell antigen receptor signaling in p110delta PI 3-kinase mutant mice. Science 2002;297:1031-4
   PubMed Web of Science ®Google Scholar
• Jou ST, Carpino N, Takahashi Y, et al. Essential, nonredundant role for the phosphoinositide 3-kinase p110delta in signaling by the B-cell receptor complex. Mol Cell Biol 2002;22:8580-91
   PubMed Web of Science ®Google Scholar
• Clayton E, Bardi G, Bell SE, et al. A crucial role for the p110delta subunit of phosphatidylinositol 3-kinase in B cell development and activation. J Exp Med 2002;196:753-63
   PubMed Web of Science ®Google Scholar
• Bauer TM, Patel MR, Infante JR. Targeting PI3 kinase in cancer. Pharmacol Ther 2015;146:53-60
   PubMed Web of Science ®Google Scholar
• Blachly JS, Baiocchi RA. Targeting PI3-kinase (PI3K), AKT and mTOR axis in lymphoma. Br J Haematol 2014;167:19-32
   PubMed Web of Science ®Google Scholar
• Curran E, Smith SM. Phosphoinositide 3-kinase inhibitors in lymphoma. Curr Opin Oncol 2014;26:469-75
   PubMed Web of Science ®Google Scholar
• Fruman DA, Rommel C. PI3Kδ inhibitors in cancer: rationale and serendipity merge in the clinic. Cancer Discov 2011;1:562-72
   PubMed Web of Science ®Google Scholar
• Gilead Sciences, Inc. Zydelig Prescribing Information. 2015. Available from: http://www.zydelig.com/?s_mcid =ppc-google-patient-branded-now-approved [Last accessed 19 March 2015]
   Google Scholar
• Lannutti BJ, Meadows SA, Herman SE, et al. CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood 2011;117:591-4
   PubMed Web of Science ®Google Scholar
• Meadows SA, Vega F, Kashishian A, et al. PI3Kδ inhibitor, GS-1101 (CAL-101), attenuates pathway signaling, induces apoptosis, and overcomes signals from the microenvironment in cellular models of Hodgkin lymphoma. Blood 2012;119:1897-900
   PubMed Web of Science ®Google Scholar
• Herman SE, Gordon AL, Wagner AJ, et al. Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals. Blood 2010;116:2078-88
   PubMed Web of Science ®Google Scholar
• Fiorcari S, Brown WS, McIntyre BW, et al. The PI3-kinase delta inhibitor idelalisib (GS-1101) targets integrin-mediated adhesion of chronic lymphocytic leukemia (CLL) cell to endothelial and marrow stromal cells. PLoS One 2013;8:e83830
   PubMed Web of Science ®Google Scholar
• Hoellenriegel J, Meadows SA, Sivina M, et al. The phosphoinositide 3’-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood 2011;118:3603-12
   PubMed Web of Science ®Google Scholar
• Jin F, Robeson M, Zhou H, et al. Pharmacokinetics, metabolism and excretion of idelalisib. Blood 2013;122:5570
   Google Scholar
• Jin F, Robeson M, Zhou H, et al. Evaluation of the effect of idelalisib on the QT/QTc interval in healthy subjects. Blood 2013;122:5573
   Google Scholar
• Webb HK, Chen H, Yu AS, et al. Clinical pharmacokinetics of CAL-101, a p110δ isoform-selective PI3K inhibitor, following single- and multiple-dose administration in healthy volunteers and patients with hematological malignancies. Blood 2010;116:1774
   Web of Science ®Google Scholar
• U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). Application number: 206545orig1s000. Other review(s). July, 2014
   Google Scholar
• U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). Guidance for Industry. E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs. October, 2005
   Google Scholar
• E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs: Questions and Answers. Geneva Switzerland: E14 Implementation Working Group, International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use; June 4, 2008
   Google Scholar
• Jin F, Robeson M, Zhou H, et al. The pharmacokinetics and safety of idelalisib in subjects with moderate or severe hepatic impairment. J Clin Pharmacol 2015;55(8):944-52
   PubMed Web of Science ®Google Scholar
• Jin F, Robeson M, Zhou H, et al. The pharmacokinetics and safety of idelalisib in subjects with severe renal impairment. Blood 2013;122:5572
   Google Scholar
• König J, Müller F, Fromm MF. Transporters and drug-drug interactions: important determinants of drug disposition and effects. Pharmacol Rev 2013;65:944-66
   PubMed Web of Science ®Google Scholar
• Thomas-Schoemann A, Blanchet B, Bardin C, et al. Drug interactions with solid tumor-targeted therapies. Crit Rev Oncol Hematol 2014;89:179-96
   PubMed Web of Science ®Google Scholar
• Müller F, Fromm MF. Transporter-mediated drug-drug interactions. Pharmacogenomics 2011;12:1017-37
   PubMed Web of Science ®Google Scholar
• Jin F, Robeson M, Zhou H, et al. Clinical drug interaction profile of idelalisib in healthy subjects. J Clin Pharmacol 2015;55(8):909-19
   PubMed Web of Science ®Google Scholar
• Ramamoorthy A, Pacanowski M, Bull J, Zhang L. Racial/ethnic differences in drug disposition and response: Review of recently approved drugs. Clin Pharmacol Ther 2015;97:263-73
   PubMed Web of Science ®Google Scholar
• Ling WH, Lee SC. Inter-ethnic differences–how important is it in cancer treatment? Ann Acad Med Singapore 2011;40:356-61
   PubMed Web of Science ®Google Scholar
• Jin F, Robeson M, Zhou H, et al. Pharmacokinetics and safety of idelalisib, a novel PI3Kδ inhibitor, in Japanese and Caucasian subjects. Blood 2013;122:5575
   Google Scholar
• Jin F, Robeson M, Zhou H, et al. The pharmacokinetics and safety of idelalisib in subjects with moderate or severe hepatic impairment. Blood 2013;122:5571
   Google Scholar
• Jin F, Robeson M, Zhou H, et al. The pharmacokinetics and safety of idelalisib in subjects with moderate or severe hepatic impairment. J Clin Oncol 2014;32(Suppl 5):abstract 2592
   Google Scholar
• Flinn IW, Kahl BS, Leonard JP, et al. Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphoma. Blood 2014;123:3406-13
   PubMed Web of Science ®Google Scholar
• Jin F, Zhou H, Fang L, et al. Exposure-response of idelalisib, a novel PI3Kδ inhibitor, administered as monotherapy in the treatment of hematologic malignancies. Blood 2013;122:5054
   Google Scholar
• Gopal AK, Kahl BS, de Vos S, et al. PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med 2014;370:1008-18
   PubMed Web of Science ®Google Scholar
• Wagner-Johnston ND, Gopal AK, Kahl BS, et al. Patient-reported outcomes data from a phase 2 study of idelalisib in patients with refractory indolent B-cell non-Hodgkin lymphoma (iNHL). J Clin Oncol 2014;32(Suppl):abstract e19554
   Google Scholar
• Leonard J, Wagner-Johnston ND, Coutre SE, et al. Tolerability and activity of combinations of the PI3Kδ inhibitor idelalisib (GS-1101) with rituximab and/or bendamustine in patients with previously treated, indolent non-Hodgkin lymphoma (iNHL): Updated results from a phase I study. J Clin Oncol 2013;31(Suppl):abstract 8500
   Google Scholar
• O’Brien SM, Lamanna N, Kipps TJ, et al. A phase II study of the selective phosphatidylinositol 3-kinase delta (PI3Kδ) inhibitor idelalisib (GS-1101) in combination with rituximab (R) in treatment-naive patients (pts) ≥65 years with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). J Clin Oncol 2013;31(Suppl):abstract 7005
   Google Scholar
• Coutré SE, Barrientos JC, Brown JR, et al. Management of adverse events associated with idelalisib treatment: expert panel opinion. Leuk Lymphoma 2015;1-8
   PubMedGoogle Scholar
• Jin F, Robeson M, Zhou H, et al. Evaluation of drug interaction profile of idelalisib and its major circulating metabolite, GS-563117, in healthy subjects. Blood 2013;122:5574
   Google Scholar